CAR-MA Design & Construction Service

As a pioneering advancement in cellular immunotherapy, chimeric antigen receptor macrophages (CAR-MA) have emerged as a key strategy to overcome the challenges of solid tumor treatment, owing to their unique tumor infiltration capacity, diverse antitumor mechanisms, and ability to reprogram the immunosuppressive tumor microenvironment. Creative Biolabs' CAR-MA Design and Construction Service provides comprehensive technical support spanning from antigen-binding domain optimization and intracellular signaling domain selection to the establishment of viral transduction systems. Our goal is to deliver highly efficient and target-specific CAR-MA research tools and therapeutic candidates, ultimately accelerating their preclinical validation and translational applications in solid tumor immunotherapy.

Introduction

A pivotal frontier in solid tumor immunotherapy involves overcoming the limitations of CAR-T cells, particularly their susceptibility to the immunosuppressive TME and inefficient tumor trafficking. CAR-MA therapy arises as a promising alternative, capitalizing on the unique abilities of macrophages to penetrate tumors, engage in antigen presentation, and remodel the immunosuppressive niche. Mastering the design and construction of CAR-MA, through tailored signaling domains, optimal cell sourcing, and rational integration of immunomodulatory elements, is therefore central to realizing the potential of this next-generation therapeutic platform.

Fig.1 Orchestrating antitumor immunity: the mechanisms of engineered CAR-Macrophages.¹

CAR-MA Design and Construction Service at Creative Biolabs

Creative Biolabs' CAR-MA Design and Construction Service is specifically designed to overcome the intrinsic limitations of T cell therapies within the TME. Our approach transcends conventional genetic modification by integrating functional polarization and multi-modal engineering, thereby ensuring superior tumor infiltration and sustained anti-tumor activity. We deliver not only advanced cell candidates but a full strategic partnership to accelerate your therapy from concept to clinic.

What we can offer

Our CAR-MA design and construction service is powered by a flexible and advanced platform to ensure your candidate is seamlessly optimized for efficacy and clinical translation.

Our Service Process

Required starting materials:

• Target Antigen Information: The specific tumor-associated antigen sequence or antibody sequence you wish to target.
• Desired Cell Source: Indication of preferred macrophage source (Primary Monocytes, iPSC line, or specified Macrophage Cell Line).
• TME Context Data: Any available in vitro or in vivo data regarding the TME of the target indication to inform optimal macrophage polarization strategy.

Key Steps Involved:

Final Deliverables:

• Validated CAR Vector/mRNA Construct.
• Final CAR-MA Cell Product.
• Detailed development and quality control report.

Key Advantages

• One-Stop Engineering Solution: An integrated service covering initial CAR construct design, custom vector production, cell sourcing, genetic transduction, and functional validation, eliminating technical handoff risks.
• Customized CAR Domain Optimization: We custom-engineer the CAR sequence, focusing on crucial signaling motifs (e.g., ITAM-like, novel co-stimulatory) to maximize targeted phagocytic flux and M1 polarization potential for superior tumor killing.
• Flexible Cell Source Mastery: Full capability to handle various cell sources, autologous primary monocytes, highly scalable allogeneic iPSC-derived macrophages (iMacs), and immortalized Cell Lines, ensuring the right fit for your research or clinical goal.

FAQ

Why Choose Us?

Our CAR-MA design and construction service is built upon a deep understanding of both the challenges in solid tumor immunotherapy and the latest scientific breakthroughs. we engineer CAR-MA constructs with customizable features to not only directly eliminate tumor cells but also recruit and activate endogenous T and NK cells, turning the tumor into a site of coordinated immune attack.

Customer Reviews

"Using Creative Biolabs' CAR-MA Design and Construction Service in our research has significantly improved the transduction efficiency in our primary monocyte-derived macrophages, consistently achieving over 85% CAR expression, which was critical for moving into in vivo studies. Their vector design was clearly superior to the off-the-shelf options we previously tested."— Dr. Je P*r.

"The functional data received from Creative Biolabs on cytokine release profiling was invaluable. It demonstrated a pronounced M1 polarization shift in our CAR-MA, confirming its capacity to actively reprogram the immunosuppressive tumor microenvironment, which is a major advantage over previous CAR-T attempts."— Ms. My C*z.

"Creative Biolabs successfully delivered a highly pure, iPSC-derived CAR-MA product. Their ability to handle the entire differentiation, transduction, and quality control process allowed us to save nearly six months on our preclinical timeline. The documentation for the final product was exceptional."—Dr. An R*o.

How to contact us?

To leverage our CAR-MA design and construction capabilities and expedite your therapeutic pipeline, we invite you to connect with our Lead Scientific Officers for dedicated scientific support.

Leverage our scientific expertise to accelerate your development timeline.

Reference

1. Chen, Kun et al. "CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar." Biomolecules & biomedicine vol. 24,3 465-476. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.17305/bb.2023.9675.